A 2009 Senate investigation released Monday, February 22nd provides another example of serious health consequences that could lead to wrongful deaths caused by a defective product , a questionable drug released by a pharmaceutical company.
According to HealthDay News citing the Saturday, February 20 edition of The New York Times , the Senate investigation concluded, "G.S.K. executives attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that a competing drug might reduce cardiovascular risk.” [1]
The article states, “The blockbuster type 2 diabetes drug Avandia raises users’ odds for heart attack and heart failure and should be removed from the market, according to confidential U.S. government reports.” Citing the Saturday, February 20 The New York Times edition, the article goes on to say the U.S. Food and Drug Administration (FDA) found an estimated 500 heart attacks and 300 heart failures a month could be eliminated by switching from Avandia to Actos, an alternative drug treatment. [1]
The article reports, in May 2007, a Cleveland Clinic study “found that Avandia increased a user’s odds of heart attack by 43 percent compared to those not taking the medicine.” [1] Furthermore, in 2007, the Food and Drug Administration (FDA) issued numerous alerts regarding rosiglitazone maleate, which is marketed by GlaxoSmithKline as Avandia, Avandamet and Avandaryl. The alerts called for better labeling to notify patients and doctors of the higher risk of myocardial ischema, or heart failure. [2]
If you or a loved one has been injured by a defective product or questionable drug, call Houston product liability lawyer , Brian Jensen for assistance.
[1] E.J. Mundell, Healthfinder.gov, U.S. Department of Health and Human Services: Remove Diabetes Drug Avandia From Market: FDA Documents
http://www.healthfinder.gov/news/newsstory.aspx?docid=636256
[2] U.S. Food and Drug Administration: Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) Information
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143349.htm